

Disrupting convention in women's health through continuous innovation.

Femasys is a leading biomedical innovator committed to providing women with revolutionary products as they seek solutions throughout their reproductive journey. Technological advancements in female reproductive health are long overdue, driving our focus to develop in-office, accessible, and innovative options.



Investment Highlights

MISSION

- Develop disruptive broad portfolio of products for women's health that improve patient care and healthcare economics
- Address multi-billion dollar global market opportunities in infertility treatment and diagnosis and permanent birth control with differentiated and improved approaches

DIFFERENTIATOR

- Minimal competition with well defined reimbursement strategies
- Global regulatory approvals achieved in U.S., Europe, United Kingdom, Canada, Japan, Israel, Australia & New Zealand
- Commercial-readiness with in-house CMC and device manufacturing
- Supply chain control; no reliance on third-party manufacturing

FOUNDATION

- Woman-founded and led; experienced leadership team with concentrated development expertise
- Intellectual property portfolio with over 200 patents issued globally

Solutions for Women Through the Continuum of Care

Fertility Portfolio REI/ GYN office

APPROVED: U.S., Europe, UK, Canada, Japan, Israel, Australia & New Zealand

femaSeed Intratubal insemination

femVue Fallopian tube diagnosis

femSperm Sperm handling kits (U.S. only)

Permanent Birth Control Portfolio GYN office

APPROVED: Europe, UK, New Zealand & other countries pending

femBloc Non-Surgical Permanent Birth Control

femChec Confirmation Test

Other Products GYN office

APPROVED: U.S., Europe, UK, Canada, Japan & Israel

femCerv Cervical cancer diagnosis

FemBloc – Product Candidate in U.S. Development



Commercially Available Portfolio

INFERTILITY TREATMENT

femaSeed


Intratubal Insemination

- First-line infertility treatment for targeted sperm delivery in the fallopian tube where conception occurs
- Positive clinical trial results with 26.3% of patients became pregnant, establishing more than double pregnancy rate when compared to historic intrauterine insemination (IUI) (17.5% FemaSeed versus 6.7% IUI per cycle) for similar patient population of low male sperm count¹
- Indicated for use for anyone desiring insemination (i.e. infertile woman/couple, same sex couples, single women) for a safe, effective, cost-affordable approach

1. Liu J. H., et al. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

Now offering
FemSperm
Sperm handling for the
Ob/Gyn office

No Affordable Infertility Solutions Introduced in Decades



2. https://www.cdc.gov/nchs/nsgf/key_statistics/i-keystat.htm
3. Kumar N, et al. (2015). doi: 10.4103/0974-1208.170370.
4. Levine H, et al. (2023). doi: 10.1093/humupd/dmac035.

INFERTILITY DIAGNOSIS

femVue

Fallopian Tube Evaluation with Ultrasound

- First in-office diagnostic device to assess the fallopian tubes by natural saline-air contrast using ultrasound
- Essential baseline diagnostic test for infertility and prior to insemination
Note: blocked tubes are a silent factor affecting 1 in 3 infertile women
- Immediate results provided for treatment planning
- Used with intrauterine catheter for safe, reliable, convenient, and cost-effective approach

CANCER DIAGNOSIS

femCerv

Endocervical Tissue Sampler for Cervical Cancer

- Virtually pain-free tissue sampler for increased patient compliance
- Designed to capture comprehensive sample with minimal contamination



Product Candidate in U.S. & Commercially Available in Select European Countries


femBloc

Non-Surgical Permanent Birth Control

- Potential to be the safest and most natural approach at substantially less cost than the long-standing surgical alternative
Note: no implant, no hormones, no incisions, and no anesthesia
- Positive clinical trial results with 0% pregnancy rate, establishing compelling evidence of efficacy. No new safety concerns through 5-years and no serious adverse events¹
- FDA approved IDE to conduct Stage III pivotal clinical trial (the "FINALE" trial, NCT05977751); trial enrollment underway
- Over 100 years of stagnant innovation could lead to \$20 billion market expansion opportunity for FemBloc in the U.S. alone

Currently
enrolling in FINALE
pivotal trial for U.S.
approval

Lack of Innovation in Last Century



1. Liu, J. H., et al. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
2. Jones et al. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. National health statistics reports; no 60. Hyattsville, MD: National Center for Health Statistics; 2012.
3. Daniels et al. Current contraceptive status among women aged 15-49: United States, 2017-2019. NCHS Data Brief, no 388. Hyattsville, MD: National Center for Health Statistics; 2020.
4. National health statistics reports; no 60. Hyattsville, MD: National Center for Health Statistics; 2012.
5. Martinez GM. Receipt of family planning services in the United States: 2022-2023. NCHS Data Brief, no 520. Hyattsville, MD: National Center for Health Statistics; 2024. DOI: <https://dx.doi.org/10.15620/cdc/169629>

This Corporate Overview contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, results of clinical trials and other future conditions. Words such as, but not limited to, "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements.

Contact

femasys.com
770-500-3910
Customer service:
877-336-2562

Femasys Inc.
3950 Johns Creek Court,
Suite 100
Suwanee, Georgia 30024
Main: 404-521-4219